A novel UGT1A1 gene mutation causing severe unconjugated hyperbilirubinemia: a case report

Xiaoxia Shi, Sem Aronson, Ahmed Sharif Khan and Piter J. Bosma

Abstract

Background: Crigler-Najjar syndrome (CNs) presents as unconjugated hyperbilirubinemia, as a result of UGT1A1 deficiency, and can be categorized in a severe (type I) and mild (type II) phenotype. CNs type II patients usually benefit from phenobarbital treatment that induces residual UGT1A1 activity.

Case presentation: Here we present a CNs type II patient that is not responsive to phenobarbital treatment, which can be explained by two heterozygous mutations in the UGT1A1 gene. A 3 nucleotide insertion in the HNF-1α binding site in the proximal promoter previously reported in a Crigler-Najjar patient on one allele and a novel two nucleotide deletion in exon 1, resulting in a frameshift and a premature stop codon.

Conclusion: In newly diagnosed CNs patients with unconjugated bilirubin levels consistent with CNs type II but that are unresponsive to phenobarbital treatment, disruption of the HNF-1α binding site in the proximal promoter should be considered as a probable cause. Upon confirming a mutation in the HNF-1α site, phenobarbital treatment should be stopped or at least be reconsidered because of its sedative effects and its teratogenic properties.

Keywords: Crigler-Najjar syndrome, UGT1A1, HNF-1α, Genetic analysis

Background

Crigler-Najjar syndrome (CNs) is a rare inherited liver disorder with a severely impaired metabolism of bilirubin, resulting in the accumulation of neurotoxic unconjugated bilirubin.

This deficiency of bilirubin glucuronidation is caused by mutations in the UGT1A1 gene encoding uridine diphosphate glucuronosyl transferase, resulting in impaired enzyme activity [1]. Clinically two types of CNs are recognized. In the most severe form, CNs type I, bilirubin glucuronidation is completely lacking, while in type II, some residual activity is present. The response to phenobarbital, that induces the expression of UGT1A1 by the mediating the binding of the constitutive androstane receptor (CAR; NR1|3) to the pBREM promoter region, is used in the clinic to distinguish both forms. In this report, we describe a second patient with a serum bilirubin level normally seen in Type II that is unresponsive to phenobarbital.

Case presentation

A 14-year old female patient from Bangladesh presented with serum total bilirubin levels around 250 μmol/L and conjugated bilirubin (measured as direct bilirubin using the Diazo method) of around 10 μmol/L, indicating a predominantly unconjugated hyperbilirubinemia. According to her parents’ description, her weight at birth was around 2000 g and 4 days after birth, her skin turned yellow. Clinical assessment revealed an unconjugated hyperbilirubinemia of 220 μmol/L without signs of erythrocyte hemolysis (major cause: ABO or Rh incompatibility). After undergoing phototherapy for 4 h a day for 4 consecutive days the serum total bilirubin levels were reduced to 153 μmol/L.

The parents were advised to keep their daughter in the sunlight, but after a few months her serum total bilirubin increased again to over 300 μmol/L. From this point onward, the patient did not receive treatment and no clinical data is available because the family lives in the countryside and has limited access to medical care. Between the
age of 14 and 17 years her serum total bilirubin levels have been monitored and where stable around 200–250 μmol/L. Liver damage markers in serum were low (ALT) and a hemolytic cause of the hyperbilirubinemia was excluded with normal hemoglobin and reticulocyte levels (Table 1). These serum bilirubin levels without any treatment are in line with those seen in Crigler-Najjar syndrome (CNs) type II, indicating a partial deficiency of UGT1A1. However, inducing the residual UGT1A1 activity by administering phenobarbital (30 mg/day) did not result in a significant change in total bilirubin (Table 1). The coding region and intron-exon boundaries of the UGT1A1 gene of the patient and parents was sequenced to determine what caused UGT1A1 deficiency and the absence of a response to phenobarbital.

**Table 1** Laboratory results between 2015 and 2018 show an unconjugated hyperbilirubinemia without signs of liver damage or hemolysis.

| Date       | Test                  | Result | Unit |
|------------|-----------------------|--------|------|
| 29/08/2018 | Total bilirubin       | 241    | μmol/L |
|            | Albumin               | 36     | g/L   |
| 15/10/2017 | Total bilirubin       | 251.4  | μmol/L |
|            | Direct bilirubin      | 10.2   | μmol/L |
| 20/12/2016 | Total bilirubin       | 217.6  | μmol/L |
|            | Albumin               | 46     | g/L   |
| 24/05/2016 | Total bilirubin       | 255    | μmol/L |
| 23/03/2016 | Total bilirubin       | 214.2  | μmol/L |
|            | Alanine aminotransferase (ALT) | 22 | U/L |
| 27/12/2015 | Total bilirubin       | 210.7  | μmol/L |
|            | Direct bilirubin      | 1.7    | μmol/L |
|            | Alkaline Phosphatase (ALP) | 87 | U/L |
|            | Gamma-GT (γ-GT)       | 18     | U/L   |
| 21/12/2015 | Hemoglobin            | 12.20  | g/dL   |
|            | Reticulocyte          | 0.86   | %     |
| 20/12/2015 | Total bilirubin       | 247    | μmol/L |
|            | ALT                   | 21     | U/L   |

Sequencing of the UGT1A1 gene coding and promoter region
Sanger sequencing was used to determine the nucleotide sequence of amplified fragments of UGT1A1 gene and promoter region as previously described [2, 3]. The purified amplicons were sequenced using the internal primers listed in Additional file 1: Table S1.

Genetic analysis of the UGT1A1 gene and promoter
The patient was found to have two heterozygous mutations in the UGT1A1 gene (Fig. 1). The first is a 3 nucleotides insertion in the HNF-1α binding site in the proximal promoter, which was also found in her mother. The second mutation is a two nucleotides deletion in exon 1 (266_267delGT), which was found in her father. This two nucleotide deletion has not been described in literature before and results in a frameshift with a predicted premature stop codon at position 279_281TAG in exon 1.

Discussion and conclusion
Here we present a patient with an unconjugated serum bilirubin level reported for patients with CNs type II [4], that does not respond to phenobarbital treatment. The patient appeared to be heterozygous for two different UGT1A1 mutations.

The mutation derived from her mother, a 3 nucleotide insertion in the HNF-1α binding site in the proximal promoter, was identical to the mutation we found in a CNs patient with a similar phenotype that we reported recently,
this 3 nucleotide insertion caused a strong reduction of basal promoter activity (~95%) and made the promoter non-responsive to CAR activation and to a potential alternative treatment via PXR activation with rifampicin which were confirmed by the functional promoter studies in that report. Due to this mutation, a minute amount of mRNA will be transcribed from this allele, which encodes for a minimal amount of normally active protein, and renders this allele unresponsive to UGT1A1 inducing drugs, including phenobarbital treatment.

The two nucleotide deletion in exon 1 of the UGT1A1 gene, inherited from her father, is a novel mutation. This mutation has not been described before and is predicted to result in a premature stop codon by frameshift leading to the formation of a truncated and inactive enzyme that will most likely be degraded.

The combination of these two mutated alleles results in a severely impaired UGT1A1 function, which is in line with the high levels of unconjugated hyperbilirubin seen in this patient. Unconjugated bilirubin levels in serum of this patient were comparable to that seen in the previous patient with an identical HNF-1α mutation, indicating the phenotype results from this mutation only. Since, the HNF-1α mutation renders the gene unresponsive to transcriptional activation of the UGT1A1 gene by phenobarbital, phototherapy and liver transplantation are currently the only therapeutic options.

We report a second patient with a CNs type II phenotype that is unresponsive to phenobarbital treatment due to a mutated HNF-1α binding site, in combination with a novel nonsense mutation. In newly diagnosed CNs patients with a similar phenotype, looking for mutations in the HNF1a binding site seems a good strategy. Upon confirming presence of a mutated HNF-1α binding site the use of phenobarbital should be reconsidered in view of its sedative effect and specifically in women, because of its reported teratogenic properties [5].

**Additional file**

**Additional file 1:** Table S1. Primer used to amplify UGT1A1 gene. (DOCX 18 kb)

**Abbreviations**

ALT: Alanine transaminase; CNs: Crigler-Najjar syndrome; HNF-1α: Hepatocyte nuclear factor 1α; UGT1A1: UDP-glucuronosyltransferase 1 A1

**Acknowledgments**

We thank the family member who sent us samples and provided clinical information for our study. XS is recipient of a fellowship of the China Scholarship Council (CSC).

**Authors’ contributions**

XS and PB have carried out the molecular genetic studies and the sequence alignment and drafted the manuscript. SA contributed to write the manuscript. ASK provided the clinical information and samples. All authors read and approved the final manuscript.

**Funding**

No applicable.

**Availability of data and materials**

All used data and materials are available upon request, please contact P.J. Bosma.

**Ethics approval and consent to participate**

Because only retrospective data was collected for this case report, the Medical Research Involving Human Subjects Act (WMO, local regulation) does not apply and official approval of this study by our local ethics committee is not required.

**Consent for publication**

Formal written consent for genetic analysis and publication was provided by the patient and her parents.

**Competing interests**

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

**Author details**

1. Amsterdam UMC, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology and Metabolism, Meibergdreef 69-71, 1105 BK, Amsterdam, The Netherlands. 2. Square Pharmaceuticals Ltd, BD, Dhaka Unit, Kallakair, Gazipur, Bangladesh.

Received: 6 December 2018 Accepted: 22 May 2019

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.